Ads
related to: treatment for giardia in horses
Search results
Results From The WOW.Com Content Network
Fenbendazole is a broad spectrum benzimidazole anthelmintic used against gastrointestinal parasites including: giardia, roundworms, hookworms, whipworms, the tapeworm genus Taenia (but not effective against Dipylidium caninum, a common dog tapeworm), pinworms, aelurostrongylus, paragonimiasis, strongyles, and strongyloides that can be administered to sheep, cattle, horses, fish, dogs, cats ...
Veterinary parasitology is a branch of veterinary medicine that deals with the study of morphology, life-cycle, pathogenesis, diagnosis, treatment, and control of eukaryotic invertebrates of the kingdom Animalia and the taxon Protozoa that depend upon other invertebrates and higher vertebrates for their propagation, nutrition, and metabolism without necessarily causing the death of their hosts.
pergolide – dopamine receptor agonist used for the treatment of pituitary pars intermedia dysfunction in horses; phenobarbital – anti-convulsant used for seizures; phenylbutazone – nonsteroidal anti-inflammatory drug (NSAID) phenylpropanolamine – controls urinary incontinence in dogs
Albendazole is a broad-spectrum antihelmintic and antiprotozoal agent of the benzimidazole type. [3] It is used for the treatment of a variety of intestinal parasite infections, including ascariasis, pinworm infection, hookworm infection, trichuriasis, strongyloidiasis, taeniasis, clonorchiasis, opisthorchiasis, cutaneous larva migrans, giardiasis, and gnathostomiasis, among other diseases.
Giardiasis is a parasitic disease caused by Giardia duodenalis (also known as G. lamblia and G. intestinalis). [3] Infected individuals who experience symptoms (about 10% have no symptoms) may have diarrhea, abdominal pain, and weight loss. [1]
Nitazoxanide alone has shown preliminary evidence of efficacy in the treatment of chronic hepatitis B over a one-year course of therapy. [17] Nitazoxanide 500 mg twice daily resulted in a decrease in serum HBV DNA in all of 4 HBeAg-positive patients, with undetectable HBV DNA in 2 of 4 patients, loss of HBeAg in 3 patients, and loss of HBsAg in one patient.